{"id":"W3167855488","doi":"10.1016/j.annonc.2021.05.353","title":"Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":278,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"Novartis Institutes for BioMedical Research; Astex Pharmaceuticals","keywords":"Medicine; Fulvestrant; Internal medicine; Hazard ratio; Population; Breast cancer; Placebo; Metastatic breast cancer; Progression-free survival; Clinical endpoint; Oncology; Cancer; Randomized controlled trial; Gastroenterology; Confidence interval; Chemotherapy; Estrogen receptor; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002414368,0.0007317237,0.001219478,0.0003004479,0.0002454072,0.0008100272,0.0003610858,0.0006208828,0.002266083],"category_scores_gemma":[0.001021932,0.0002260592,0.001526961,0.000305268,0.0003945529,0.0004441459,0.0003376311,0.001180234,0.0003319761],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004699893,"about_ca_system_score_gemma":0.0007945282,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006118026,"about_ca_topic_score_gemma":0.0027734,"domain_scores_codex":[0.9993713,0.0004179842,0.0000297236,0.0000661723,0.00004338196,0.00007145044],"domain_scores_gemma":[0.999616,0.00007839567,0.0001257238,0.0000438793,0.0000281,0.0001077933],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9198014,0.002806896,0.007039446,0.001224316,0.003030878,0.00008481448,0.00006136706,0.0009479456,0.006186002,0.0002301393,0.002996187,0.05559058],"study_design_scores_gemma":[0.8776386,0.08285765,0.02525672,0.0001529127,0.003703913,0.0002332735,0.00005179993,0.0006575242,0.001360312,0.0004464328,0.007611178,0.00002967434],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9660802,0.02186119,0.0009283213,0.001376739,0.0004256415,0.002812108,0.002936442,0.0000857307,0.00349351],"genre_scores_gemma":[0.9843322,0.005118505,0.001152412,0.001275708,0.0003069715,0.002008319,0.003291396,0.00001511321,0.002499412],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002414368,"threshold_uncertainty_score":0.01276851,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04265747474552653,"score_gpt":0.3792816454752698,"score_spread":0.3366241707297433,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}